Jasper Therapeutics receives FDA guidance for briquilimab in CSU; IND filing and first patient dose expected in H2 2023

Jasper Therapeutics, Inc.

FDA provided guidance on the proposed program for briquilimab for chronic spontaneous urticaria (CSU).
Company expects to file IND for briquilimab in CSU and dose first patient in H2 2023.
Jasper will continue engagement with FDA toward IND submission and launch of CSU clinical trial.
Updated corporate presentation posted on company website as of June 2, 2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.